Halvorsen, Mathew
Samuels, Jack
Wang, Ying
Greenberg, Benjamin D.
Fyer, Abby J. http://orcid.org/0000-0002-0944-2505
McCracken, James T.
Geller, Daniel A. http://orcid.org/0000-0001-8692-4156
Knowles, James A. http://orcid.org/0000-0002-3307-5741
Zoghbi, Anthony W.
Pottinger, Tess D.
Grados, Marco A.
Riddle, Mark A.
Bienvenu, O. Joseph
Nestadt, Paul S. http://orcid.org/0000-0002-2479-703X
Krasnow, Janice
Goes, Fernando S. http://orcid.org/0000-0001-6262-8264
Maher, Brion
Nestadt, Gerald http://orcid.org/0000-0001-9461-5249
Goldstein, David B. http://orcid.org/0000-0002-1111-2820
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (MH079489, MH079487, MH079494, MH071507, MH097993, MH097971, MH099216)
Article History
Received: 24 February 2020
Accepted: 18 May 2021
First Online: 28 June 2021
Competing interests
: D.B.G. reports equity holdings in precision medicine companies and consultancy payments from Gilead Sciences, AstraZeneca and GoldFinch Bio. All other authors declare no competing financial interests.